Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2001

View Archived Issues

HIF-1 gene therapy product in clinical trial at U. of Pittsburgh Medical Center

Neovastat pivotal trial for third cancer indication approved in U.S. and Canada

Enzon seeks FDA approval to clinically evaluate PEG-paclitaxel

Effects of CGP-3466 investigated in models of Parkinson's disease

DNA vaccine for malaria to be developed using PLASmin Complexes

BresaGen's lead anticancer compound E21R licensed to British Biotech

Viragen staged to begin U.S. clinical trials with Omniferon

Avanir begins late-stage clinical trials with new drug for neurological disorders

ETA receptor antagonists in various stages of clinical testing at Icos-Texas Biotechnology

Clinical trial commences for new antiangiogenic agent discovered by OSI and Pfizer

DU-127090 will be codeveloped by Lundbeck and Solvay for schizophrenia

Antiviral drugs acquired by Novartis from SB

Zeldox status in Europe updated by Pfizer

Elan/Incara partnership plans immediate entry into pivotal IBD trials for OP-2000

Global rights for novel Japanese antiviral agent granted to Lilly

Name change and recent TB4 research results announced by the former Alpha 1 Biomedicals

L-739758 preserves coronary flow reserve during progressive coronary arteriostenosis in pigs

BP-2-94: an H3 receptor agonist prodrug with an interesting antiinflammatory/antinociceptive profile

New potassium channel modulators synthesized and tested by NeuroSearch

Recent patent covers Lilly's new subtype-selective metabotropic glutamate receptor antagonists

Aventis team describes preparation and use of new cell adhesion, migration inhibitors

Chemokine receptor antagonists in GlaxoSmithKline portfolio

Novel antiinflammatory agents described by Bayer group

Inhibitors of PTP1B and their use covered in patent issued to Merck Frosst

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.